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The Food and Drug Administration and varenicline:
should risk communication be improved?
Patients and clinicians are likely to interpret the FDA Black
Box warning about serious adverse neuropsychiatric adverse
events as implying a causal effect of varenicline. This
warning does not reﬂect current scientiﬁc evidence
accurately and should be revised.
On 11 May 2006, the US Food and Drug Administra-
tion (FDA) approved varenicline (Chantix, Champix) for
use in smoking cessation; it was the ﬁrst oral non-nicotine
treatment licensed by the FDA since bupropion in 1997
[1]. However, it was not long before concerns were raised
about the neuropsychiatric safety of the medicine. Anec-
dotal reports from popular press and internet sites, in addi-
tion to post-marketing case reports and reports to the FDA’s
Adverse Event Reporting System (AERS), suggested that
some patients prescribed varenicline had experienced
suicidal behaviour [2]. As a result, in November 2007 the
FDA announced that they were conducting two safety
reviews of varenicline’s associations with suicidality and
neuropsychiatric adverse events not related to suicidality
[3]. Findings from these reviews were published in 2008,
with the FDA concluding that ‘[varenicline] may cause
worsening of a current psychiatric illness even if it is
currently under control and may cause an old psychiatric
illness to reoccur’ [4]. In July 2009 the FDA went further,
mandating that varenicline carry a ‘Black Box warning’
[5]. These warnings highlighted ‘the risk of serious neuro-
psychiatric symptoms in patients using these products’.
Symptoms included changes in behaviour, hostility, agita-
tion, depressed mood, suicidal thoughts and behaviour
and attempted suicide.
The FDA subsequently commissioned two large obser-
vational studies to investigate the potential neuropsychiat-
ric effects of varenicline using observational data from
military veterans. Pﬁzer (the manufacturer of varenicline)
was also instructed to undertake a large randomized trial:
Evaluating Adverse Events in a Global Smoking Cessation
Study (EAGLES) (NCT:01456936). Results from the
observational studies were reported in October 2011. In
the ﬁrst, 14311 patients prescribed varenicline were
matched to similar patients prescribed nicotine replace-
ment therapy (NRT) using propensity scores. Patients
prescribed varenicline were no more likely than those
prescribed NRT to be hospitalized for psychiatric problems
[hazard ratio (HR) = 0.76; 95% conﬁdence interval (95%
CI) = 0.40–1.46] [3]. In the second, 10814 patients
prescribed varenicline were matched to patients prescribed
NRT. This study also showed that patients prescribed
varenicline were no more likely to be hospitalized for
psychiatric problems (HR = 1.14; 95% CI = 0.56–2.34)
[6]. Observational studies, which can suffer from residual
confounding, could not prove that varenicline did not
cause neuropsychiatric adverse events. Nevertheless, they
provided a more robust form of evidence than the anec-
dotal and case report evidence used in the original safety
review. The FDA ‘determined that the current warnings
in the Chantix drug label, based on post marketing surveil-
lance reports, remain appropriate’ and did not remove the
Black Box warning [7].
Meanwhile, further evidence was emerging relating to
the safety of varenicline. Gunnell and colleagues found no
evidence of an increased risk of suicidal behaviour in a
cohort of 80660 patients from the UK’s General Practice
Research Database [8]. In 2013 we updated this analysis
to include data from 119546 patients, using conventional
and novel statistical methods to account for residual
confounding [9]. The ﬁndings were the same: there was
no evidence that patients prescribed varenicline had an
increased risk of fatal or non-fatal self-harm. Other
observational studies have reported similar ﬁndings [10].
In 2015 we published a meta-analysis of results from all
available randomized trials, which found that smokers
randomized to receive varenicline had similar risks of
suicide or attempted suicide to those randomized to receive
placebo (OR = 1.67, 95% CI = 0.33–8.57) [11]. In March
2015 the FDA issued a further Safety Communication, but
did not remove the Black Box warning [12]. In 2016 the
results of the EAGLES trial was published. This trial ran-
domized 8144 smokers to receive varenicline, transdermal
NRT patch, bupropion or placebo, and found that for every
100 smokers allocated to varenicline compared with NRT
there were 1.07 (95% CI = –0.08 to 2.21) fewer moderate
and severe neuropsychiatric adverse events [13].While it is
possible for trials to suffer from bias, this provides the
strongest evidence to date that varenicline does not cause
neuropsychiatric adverse events [14]. Based on the results
of this study, the European Medicines Agency (EMA)—
Europe’s main drug regulator—lifted the warning about
possible suicidal risks from varenicline in April 2016 [15].
BLACK BOX WARNINGS, WHAT ARE
THEY?
Black Box warnings are the strongest warning the FDA
issues, and they are ‘designed to call attention to serious
or life-threatening risks’ [3]. These warnings must be
issued with all prescriptions of the drug in question. The
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FDA’s only escalation after a Black Box warning is to force a
drug to be recalled or withdrawn from the market. Black
Box warnings indicate either when there is a serious
adverse reaction with ‘some basis to believe there is a
causal relationship between the drug and the occurrence
of the adverse event’ or to ‘highlight important information
for prescribers’ [3].
CORRELATION DOES NOT EQUAL
CAUSATION
Patients prescribed medications are often at higher risk
of adverse events than the general population, even
before they start treatment. Therefore, the fact that a
medication is associated with adverse events is not
necessarily informative for patients. In the case of
varenicline, people who smoke are very different from
the general population; on average they are poorer,
sicker and more likely to have mental health prob-
lems [16]. Smokers prescribed varenicline recorded in
the FDA’s AERS were likely to be at increased risk of
neuropsychiatric problems before they were prescribed
varenicline. The case reports could not take these differ-
ences into account in their analysis. Thus, the adverse
event reports are likely to be unreliable evidence of the
differences in risks of adverse events faced by smokers if
they took varenicline or other treatments.
SHOULD BLACK BOX WARNINGS ONLY
BE USED FOR CAUSATION?
The only information that is useful for patients making
treatment decisions is evidence about the causal effects
of medications. This should, ideally, be obtained from an
adequately powered randomized trial or meta-analyses
of randomized trials. However, there are many instances
where randomized trials are not feasible. In the absence
of experimental data, regulators should rely upon well-
conducted observational studies. At minimum, these
studies should control for a rich set of baseline con-
founders, use appropriate control groups and avoid or
account for as many potential biases as possible [17].
Case reports without an adequate control group are
unlikely to be sufﬁcient evidence of causation except
when the causal effects are extremely large, the adverse
event is very rare and the adverse events are not
related to the potential confounders [18]. However,
the incidence of adverse events in treated groups is
useful information for prescribers, even if they are not
caused by the medication. Should the FDA use Black
Box warnings to report information both about the
causal effects of medications and patients’ baseline risk
of adverse events?
IMPLICATIONS FOR VARENICLINE
Effective regulation has to balance all the evidence
regarding efﬁcacy and safety, even when evidence is
sparse and potentially unreliable. However, false positive
signals discovered in case reports can be damaging—
the reduced uptake of the measles, mumps and rubella
(MMR) vaccine after it was linked (incorrectly) to autism
provides a cautionary example in this context. The Black
Box warnings issued for varenicline may have confused
smokers and physicians about the strength of the scien-
tiﬁc evidence about varenicline’s neuropsychiatric risks.
This is because they may have interpreted the Black
Box warning as reporting causal adverse drug reactions.
This has serious consequences; fewer people are likely to
have been prescribed varenicline as a result of these
warnings. Sales of varenicline fell steadily from 2007
to 2014 after adjusting for inﬂation (Fig. 1). While we
cannot be sure how the FDA’s warning affected prescrib-
ing, the safety concerns may have led to fewer people
quitting smoking [18]. In addition, Pﬁzer has been
subject to litigation in the United States over potential
neuropsychiatric adverse effects of varenicline which
they settled out of court at a cost of US$288 million
[19]. Few may have sympathy for a multi-billion dollar
pharmaceutical company, given the well-documented
misdeeds of big pharma [20]. None the less, Black Box
warnings can also impose signiﬁcant costs on companies
developing new treatments, and potentially reduce
innovation.
WHAT SHOULD WE DO NOW?
From the ﬁrst warnings about potential neuropsychiatric
adverse effects of varenicline in November 2007 to the
present, 4.1 million people are likely to have died from
smoking-related disease in the United States alone [16].
The EMA has already updated its guidance on varenicline
Figure 1 Pﬁzer revenues from varenicline ($m) by year
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and removed its Black Triangle warnings on varenicline’s
product labelling. It is time for the FDA to do the same.
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